Literature DB >> 28283218

Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model.

Nuno Alexandre1, Irina Amorim2, Ana Rita Caseiro3, Tiago Pereira4, Rui Alvites4, Alexandra Rêma5, Ana Gonçalves5, Guilherme Valadares6, Elísio Costa7, Alice Santos-Silva7, Miguel Rodrigues8, Maria Ascensão Lopes8, André Almeida9, José Domingos Santos8, Ana Colette Maurício4, Ana Lúcia Luís10.   

Abstract

The functional and structural performance of a 5cm synthetic small diameter vascular graft (SDVG) produced by the copolymerization of polyvinyl alcohol hydrogel with low molecular weight dextran (PVA/Dx graft) associated to mesenchymal stem cells (MSCs)-based therapies and anticoagulant treatment with heparin, clopidogrel and warfarin was tested using the ovine model during the healing period of 24 weeks. The results were compared to the ones obtained with standard expanded polyetetrafluoroethylene grafts (ePTFE graft). Blood flow, vessel and graft diameter measurements, graft appearance and patency rate (PR), thrombus, stenosis and collateral vessel formation were evaluated by B-mode ultrasound, audio and color flow Doppler. Graft and regenerated vessels morphologic evaluation was performed by scanning electronic microscopy (SEM), histopathological and immunohistochemical analysis. All PVA/Dx grafts could maintain a similar or higher PR and systolic/diastolic laminar blood flow velocities were similar to ePTFE grafts. CD14 (macrophages) and α-actin (smooth muscle) staining presented similar results in PVA/Dx/MSCs and ePTFE graft groups. Fibrosis layer was lower and endothelial cells were only detected at graft-artery transitions where it was added the MSCs. In conclusion, PVA/Dx graft can be an excellent scaffold candidate for vascular reconstruction, including clinic mechanically challenging applications, such as SDVGs, especially when associated to MSCs-based therapies to promote higher endothelialization and lower fibrosis of the vascular prosthesis, but also higher PR values.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dextran; Mesenchymal stem cells; Ovine model; PVA; Synthetic small diameter vascular graft

Mesh:

Substances:

Year:  2017        PMID: 28283218     DOI: 10.1016/j.ijpharm.2017.02.043

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  One-Pot Covalent Grafting of Gelatin on Poly(Vinyl Alcohol) Hydrogel to Enhance Endothelialization and Hemocompatibility for Synthetic Vascular Graft Applications.

Authors:  Muhammad Rizwan; Yuan Yao; Maud B Gorbet; John Tse; Deirdre E J Anderson; Monica T Hinds; Evelyn K F Yim
Journal:  ACS Appl Bio Mater       Date:  2019-11-19

2.  Dental pulp stem cells and Bonelike® for bone regeneration in ovine model.

Authors:  J M Campos; A C Sousa; A R Caseiro; S S Pedrosa; P O Pinto; M V Branquinho; I Amorim; J D Santos; T Pereira; C M Mendonça; A Afonso; L M Atayde; A C Maurício
Journal:  Regen Biomater       Date:  2018-12-22

3.  Establishment of a Sheep Model for Hind Limb Peripheral Nerve Injury: Common Peroneal Nerve.

Authors:  Rui D Alvites; Mariana V Branquinho; Ana C Sousa; Federica Zen; Monica Maurina; Stefania Raimondo; Carla Mendonça; Luís Atayde; Stefano Geuna; Artur S P Varejão; Ana C Maurício
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

4.  Design, characterization and in vivo performance of synthetic 2 mm-diameter vessel grafts made of PVA-gelatin blends.

Authors:  M Atlan; T Simon-Yarza; J M Ino; V Hunsinger; L Corté; P Ou; R Aid-Launais; M Chaouat; D Letourneur
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

5.  Human umbilical cord blood plasma as an alternative to animal sera for mesenchymal stromal cells in vitro expansion - A multicomponent metabolomic analysis.

Authors:  A R Caseiro; G Ivanova; S S Pedrosa; M V Branquinho; P Georgieva; P P Barbosa; J D Santos; R Magalhães; P Teixeira; T Pereira; A C Maurício
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.